PPT-DNA vaccination against drug resistance in chronic viral infections, example of HIV-1

Isaguliants Maria Department of Microbiology Tumor and Cell Biology Karolinska Institutet Stockholm Sweden A Kirhenstein Institute of Microbiology and Virology Riga Stradins University Riga Latvia. HIV. & . AIDS. . Hepatitis. Herpes Virus. Influenza. . Chapter 36. 1. Demographics. World-wide in 2006: 65 Million people living with HIV/AIDS. U.S.: . 1.1. Million cases to date:. 40,000 new cases each year. . Helping . the . Infection . Preventionist. . Interpret . Antibiograms. Walter Phillips, BS, MS, PhD. Director of Microbiology. TriStar Healthcare System . Acknowledge. I would like to acknowledge the following contributors to this presentation:. VL-5 . Dec.1st 2013. Mohammed El-Khateeb. Structures of the Respiratory System. Structures . of the Upper Respiratory System. ,. Nose. Nasal cavity. Pharynx. Tonsils. Mucus. Structures of the Lower Respiratory . .. About company. BIOFARMA . - is leading Ukrainian pharmaceutical enterprise, that. . produce and develop innovative drugs, made from . human blood plasma, recombinant drugs and medicines on the basis of spore-forming bacteria.. Camille Angle, Meagan Bardan, Hanna Schimjawicz and Sean Tabarah. PHM142 Fall . 2018. Instructor: . Ms. Maya Latif. Coordinator: Dr. J. Henderson. HIV Attachment and Penetration. Wilen, C. B., Tilton, J. C., & Doms, R. W. D. (2012). HIV: Cell binding and entry. . Virus (HIV) . Infection. Zoya. . Minasyan. RN-MSN-. Edu. Significance of Problem. Globally. 33 million living with HIV. 2.7 million new infections each year. 2 million HIV-related deaths each year. Define drug resistance. Identify . factors that influence drug resistance. .. Identify . strategies for minimizing development of drug resistance.. Identify strategies for responding to detection of moderate to high levels of drug resistant HIV.. in the United States, 2013 TABLE OF CONTENTS Foreword .............................................................................................. . Executive Summary .............................. RESISTANCE Interagency Task Force on Antimicrobial Resistance Co - Chairs: Centers for Disease Control and Prevention Food and Drug Administration National Institutes of Health Participating Agencie s selective toxicity. , . spectrum of activity. , . mode of action. , . side effects. , and . resistance of microorganisms . Antimicrobial Side Effects . Allergy. Ototoxicity, nephrotoxicity, and hepatotoxicity. exanthem. :. Exanthem. is the term classically used to describe a widespread rash associated with fever in childhood.. Maternal antibody gives protection for the first 6–12 months of life and infection occurs thereafter.. Antimicrobial drugs . have the ability to . injure or kill . an . invading microorganism without harming the cells of the host . (biochemical differences that exist between microorganisms and human). In most instances, this . Southeast Asia, east Asia and Oceania. High income. Latin America and Caribbean. Central Europe, eastern Europe and central Asia. South Asia. Sub-Saharan Africa. Antimicrobial resistance (AMR): . Deaths . Kabore HJ, Li X, Allison RD, Avagyan T, Mihigo R, Takashima Y, et al. Effects of Decreased Immunization Coverage for Hepatitis B Virus Caused by COVID-19 in World Health Organization Western Pacific and African Regions, 2020. Emerg Infect Dis. 2022;28(13):217-224. https://doi.org/10.3201/eid2813.212300.